Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial
JE Rosenberg, MD Galsky, T Powles, DP Petrylak, J Bellmunt, Y Loriot, A Necchi, J Hoffman-Censits, JL Perez-Gracia, MS van der Heijden, R Dreicer, I Durán, D Castellano, A Drakaki, M Retz, SS Sridhar, P Grivas, EY Yu, PH O’Donnell, HA Burris, S Mariathasan, Y Shi, E Goluboff, D Bajorin · 2024
Read Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial by JE Rosenberg, MD Galsky, T Powles, DP Petrylak, J Bellmunt, Y Loriot, A Necchi, J Hoffman-Censits, JL Perez-Gracia, MS van der Heijden, R Dreicer, I Durán, D Castellano, A Drakaki, M Retz, SS Sridhar, P Grivas, EY Yu, PH O’Donnell, HA Burris, S Mariathasan, Y Shi, E Goluboff, D Bajorin (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11667038.txt.
Description
The authors give the final results of the IMvigor210 trial, which tested the drug atezolizumab alone in patients with advanced bladder cancer that had spread. Earlier reports showed benefit with manageable side effects. This paper adds long-term follow-up. One group of 119 patients could not take standard cisplatin treatment and had no prior therapy. A second group of 310 patients had already received platinum-based treatment.
Patients received the drug every 21 days until the cancer grew or side effects became too much. In the first group, about 23.5 percent of tumors shrank, and about 28 percent shrank in those whose tumors showed high levels of the PD-L1 marker. The team also reports survival, results by marker status, and safety over the full follow-up. Median follow-up reached about 96 months in the first group and 46 months in the second, giving a mature view of the drug's effects.
Catalog record
| CREATOR | JE Rosenberg, MD Galsky, T Powles, DP Petrylak, J Bellmunt, Y Loriot, A Necchi, J Hoffman-Censits, JL Perez-Gracia, MS van der Heijden, R Dreicer, I Durán, D Castellano, A Drakaki, M Retz, SS Sridhar, P Grivas, EY Yu, PH O’Donnell, HA Burris, S Mariathasan, Y Shi, E Goluboff, D Bajorin |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |